Welcome to our dedicated page for Atea Pharmaceuticals SEC filings (Ticker: AVIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Atea Pharmaceuticals’ dense biotech disclosures can feel like deciphering lab notes written in legalese. Phase 3 trial endpoints, cash-runway projections, and nuanced risk factors are scattered across hundreds of pages—exactly where critical clues hide for COVID-19 and hepatitis C investors.
Stock Titan turns that challenge into clarity. Our platform delivers AI-powered summaries that transform every Atea Pharmaceuticals quarterly earnings report 10-Q filing into an accessible brief, highlight cash-burn trends inside the annual report 10-K simplified, and flag material trial results through Atea Pharmaceuticals 8-K material events explained. Need to track executive sentiment? Receive real-time alerts on Atea Pharmaceuticals Form 4 insider transactions — the same data many professionals watch minutes after it posts to EDGAR.
Whether you’re screening Atea Pharmaceuticals insider trading Form 4 transactions for buying patterns, comparing pipeline updates across filings, or simply understanding Atea Pharmaceuticals SEC documents with AI, our coverage is complete. You’ll find:
- Instant, searchable access to every 10-K, 10-Q, 8-K, S-1, and DEF 14A proxy statement executive compensation disclosure
- AI commentary that links trial milestones to revenue projections for swift Atea Pharmaceuticals earnings report filing analysis
- Push notifications for Atea Pharmaceuticals executive stock transactions Form 4 in real time
Save hours combing through technical appendices. With Stock Titan, Atea Pharmaceuticals SEC filings explained simply are just a click away, giving you the insight to act before the market does.
Atea Pharmaceuticals (AVIR) filed its Q3 2025 10-Q, highlighting continued investment in its hepatitis C program and a strong liquidity position. The company reported a net loss of $42.0 million for the quarter and $113.5 million year-to-date, driven primarily by R&D as Phase 3 trials advance. R&D was $38.3 million in Q3, with HCV external costs a key component.
Cash, cash equivalents and marketable securities totaled $329.3 million as of September 30, 2025, and management believes this will fund operations through 2027. The balance sheet shows total assets of $343.0 million and stockholders’ equity of $315.8 million. Atea completed its $25.0 million share repurchase program in 2025, including 3,054,195 shares bought for $11.4 million in Q3. Shares outstanding were 78,126,796 as of November 10, 2025.
The Phase 3 HCV program (C-Beyond in the US/Canada and C-Forward ex-North America) began enrollment in April and June 2025. Atea maintains an at-the-market facility with Jefferies for up to $200.0 million; no shares were sold as of September 30, 2025. The company previously reduced headcount by ~25%, targeting aggregate savings of approximately $15 million through 2027.
Atea Pharmaceuticals, Inc. (AVIR) furnished its quarterly earnings press release for the three months ended September 30, 2025. The company reported this under Item 2.02 of Form 8-K on November 12, 2025. The press release is furnished as Exhibit 99.1 and incorporated by reference.
The Item 2.02 information, including Exhibit 99.1, is expressly stated as not deemed “filed” under Section 18 of the Exchange Act and not incorporated into Securities Act or Exchange Act filings unless specifically referenced. The filing also lists Exhibit 104 for the cover page Inline XBRL tags.
Form 4 filing (24-Jun-2025) reveals that Atea Pharmaceuticals (AVIR) director Franklin M. Berger increased his ownership through equity-based compensation granted on 20-Jun-2025. A total of 29,600 previously issued restricted stock units (RSUs) vested and converted into common shares (Code M) at a $0.00 cost, lifting his direct holdings to 506,497 shares. Concurrently, Berger received 29,600 new RSUs that will vest at the next annual meeting or one-year anniversary, and 41,200 stock options with a $3.25 exercise price expiring 19-Jun-2035, vesting monthly over 12 months. No shares were sold. The transactions signal net insider accumulation while introducing modest potential dilution through the new RSUs and options.
Form 4 highlights for Atea Pharmaceuticals, Inc. (AVIR)
- Reporting person: Bruce Polsky, Director.
- Transaction date: 20 Jun 2025; filing date 24 Jun 2025.
- Non-derivative shares: 29,600 common shares acquired at $0.00 upon RSU vesting; total direct ownership now 95,206 shares.
- New derivative grants:
- 29,600 Restricted Stock Units (RSUs) that vest on the earlier of the 2026 annual meeting or 1-year anniversary of grant.
- 41,200 stock options with a $3.25 exercise price, vesting monthly over 12 months and expiring 19 Jun 2035.
- Derivative disposition: 29,600 RSUs converted to common stock (code “M”), leaving zero balance for that award.
The filing reflects routine director equity compensation—no open-market buying or selling—and increases Mr. Polsky’s direct equity stake in AVIR. No cash outlay was required for the RSU conversion; the new option strike establishes the cost basis for potential future purchases.
FAQ
What is the current stock price of Atea Pharmaceuticals (AVIR)?
What is the market cap of Atea Pharmaceuticals (AVIR)?
